← Back to patent-cliff list
Budesonide oral suspension (Dr Falk Pharma)
Tier C — Watch / tradeBudesonide oral suspension (Dr Falk Pharma)
Dr Falk Pharma GmbH
Originator
2018
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR
Brand：Jorveza
Indications (approved)：Oesophageal disease
Regional status
US
-
EU
Approved
2018-01-08
China
Phase I
2022-08-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Budesonide oral suspension (Dr Falk Pharma)?
Approved indications include: Oesophageal disease.
When does the Budesonide oral suspension (Dr Falk Pharma) patent expire?
No public expiry year is available for Budesonide oral suspension (Dr Falk Pharma) yet; this page updates once verified.
How do I get a quote for Budesonide oral suspension (Dr Falk Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29